Tricida pulls in $30 mln Series B
South San Francisco-based Tricida, a biopharmaceutical company focused on treating renal disease, has raised $30 million in Series B funding. OrbiMed led the round with participation from Sibling Capital Ventures and Limulus Venture Partners.
4 March 2015•2 mins read
